Whom and Where Are We Not Vaccinating? Coverage after the Introduction of a New Conjugate Vaccine against Group A Meningococcus in Niger in 2010

MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African “meningitis belt”. In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sung Hye, Pezzoli, Lorenzo, Yacouba, Harouna, Coulibaly, Tiekoura, Djingarey, Mamoudou H., Perea, William A., Wierzba, Thomas F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262782/
https://www.ncbi.nlm.nih.gov/pubmed/22276104
http://dx.doi.org/10.1371/journal.pone.0029116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262782/
https://www.ncbi.nlm.nih.gov/pubmed/22276104
http://dx.doi.org/10.1371/journal.pone.0029116

Ejemplares similares